Shorts Action: What’s Ahead for Acceleron Pharma Incorporated (NASDAQ:XLRN) After More Shorted Shares?

November 22, 2016 - By Louis Casey   ·   0 Comments

Shorts Action: What’s Ahead for Acceleron Pharma Incorporated (NASDAQ:XLRN) After More Shorted Shares?

The stock of Acceleron Pharma Incorporated (NASDAQ:XLRN) registered an increase of 2.77% in short interest. XLRN’s total short interest was 2.28M shares in November as published by FINRA. Its up 2.77% from 2.22 million shares, reported previously. With 264,400 shares average volume, it will take short sellers 9 days to cover their XLRN’s short positions. The short interest to Acceleron Pharma Incorporated’s float is 7.26%. The stock decreased 0.29% or $0.11 during the last trading session, hitting $37.85. Acceleron Pharma Inc (NASDAQ:XLRN) has risen 24.34% since April 20, 2016 and is uptrending. It has outperformed by 19.79% the S&P500.

Acceleron Pharma Inc. is a United States clinical stage biopharmaceutical company. The company has a market cap of $1.42 billion. The Firm focuses on discovering and developing therapies to treat a range of diseases. It currently has negative earnings. The Company’s therapeutic candidate, luspatercept, is being evaluated in Phase III studies for the treatment of the hematologic diseases myelodysplastic syndromes and beta-thalassemia.

Insitutional Activity: The institutional sentiment decreased to 1 in Q2 2016. Its down 0.49, from 1.49 in 2016Q1. The ratio worsened, as 15 funds sold all Acceleron Pharma Inc shares owned while 32 reduced positions. 20 funds bought stakes while 50 increased positions. They now own 28.02 million shares or 2.80% less from 28.83 million shares in 2016Q1.
State Board Of Administration Of Florida Retirement Systems holds 0% or 18,078 shares in its portfolio. D E Shaw & Co holds 0% of its portfolio in Acceleron Pharma Inc (NASDAQ:XLRN) for 35,205 shares. Citadel Limited Liability Company last reported 0.01% of its portfolio in the stock. Pacad Investment Ltd accumulated 3,900 shares or 0.02% of the stock. Proshare Advisors Ltd Llc holds 31,057 shares or 0.01% of its portfolio. Blackrock Mngmt Limited Company has 0.01% invested in the company for 134,458 shares. Winslow Evans And Crocker owns 1,260 shares or 0% of their US portfolio. Principal Group Inc owns 97,100 shares or 0% of their US portfolio. Prudential Fincl holds 81,500 shares or 0% of its portfolio. The Pennsylvania-based Mycio Wealth Prtnrs Llc has invested 0% in Acceleron Pharma Inc (NASDAQ:XLRN). Product Partners has 52,101 shares for 0.14% of their US portfolio. Voya Investment Mgmt Limited Liability has 11,582 shares for 0% of their US portfolio. Smith Asset Gp L P last reported 5,940 shares in the company. Pnc Service Group Inc Inc accumulated 5,055 shares or 0% of the stock. Hamilton Lane Advisors Ltd Llc reported 33,340 shares or 0.55% of all its holdings.

Insider Transactions: Since May 23, 2016, the stock had 0 insider purchases, and 9 selling transactions for $58.34 million net activity. $1.12M worth of Acceleron Pharma Inc (NASDAQ:XLRN) was sold by Ertel Steven D. MCLAUGHLIN KEVIN F had sold 25,300 shares worth $860,200 on Monday, May 23. 100,000 shares with value of $3.39 million were sold by Knopf John L on Friday, July 1. Sherman Matthew L had sold 26,000 shares worth $903,143 on Friday, July 1. Quisel John D sold $689,017 worth of stock or 21,438 shares. Shares for $17.41M were sold by George Jean. Another trade for 52,486 shares valued at $1.78 million was made by Kumar Ravindra on Thursday, October 6.

Acceleron Pharma Inc (NASDAQ:XLRN) Ratings Coverage

Out of 7 analysts covering Acceleron Pharma (NASDAQ:XLRN), 5 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 71% are positive. $63 is the highest target while $40 is the lowest. The $50.60 average target is 33.69% above today’s ($37.85) stock price. Acceleron Pharma has been the topic of 10 analyst reports since August 13, 2015 according to StockzIntelligence Inc. The stock has “Neutral” rating given by Citigroup on Thursday, September 29. The firm has “Outperform” rating by Credit Suisse given on Thursday, January 21. The firm earned “Outperform” rating on Monday, January 18 by FBR Capital. The firm earned “Outperform” rating on Monday, February 1 by Oppenheimer. Oppenheimer initiated Acceleron Pharma Inc (NASDAQ:XLRN) rating on Friday, November 20. Oppenheimer has “Outperform” rating and $58 price target. The stock of Acceleron Pharma Inc (NASDAQ:XLRN) earned “Neutral” rating by Janney Capital on Thursday, December 17. The firm earned “Overweight” rating on Wednesday, April 27 by Barclays Capital. The rating was maintained by FBR Capital on Friday, January 15 with “Outperform”. The company was maintained on Monday, June 13 by Barclays Capital. Morgan Stanley initiated Acceleron Pharma Inc (NASDAQ:XLRN) on Thursday, August 13 with “Overweight” rating.

XLRN Company Profile

Acceleron Pharma Inc., incorporated on June 13, 2003, is a clinical-stage biopharmaceutical company. The Firm is focused on the discovery, development and commercialization of therapeutic candidates that are based on the mechanisms that the human body uses to regulate the growth and repair of its cells and tissues. The Company’s segment operates through discovery, development and commercialization of protein therapeutics for cancer and rare diseases. The Company’s research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-b) protein superfamily. The Firm focuses on discovering and developing therapeutic candidates that target a group of approximately 30 secreted proteins, or ligands, that are collectively referred to as the TGF-b superfamily. These ligands bind to subsets of 12 different receptors on the surface of cells, triggering intra-cellular changes in gene expression that guide cell growth and differentiation. The TGF-b superfamily ligands and their receptors represent an under-explored and diverse set of drug targets.

More recent Acceleron Pharma Inc (NASDAQ:XLRN) news were published by: which released: “/quotes/zigman/3870025/realtime” on September 19, 2013. Also published the news titled: “Acceleron Pharma tabs Bayer exec as next CEO” on September 27, 2016.‘s news article titled: “Acceleron Pharma Rises Despite Q3 Revenue Miss” with publication date: November 04, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Louis Casey

Readers Comments (0)

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News